SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38170452.
- Also identified by DOI 10.1093/cid/ciad796.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
Medical subject headings
- Antiviral Agents
- SARS-CoV-2
- COVID-19 Drug Treatment